Director Johnna Temenoff
Johnna Temenoff, director of the NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT), was featured in the latest episode of Holy Shift!, a podcast from the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University on the latest news and breakthroughs in the field of biomedical research and engineering.
Joined by host Angela Gill Nelms, Temenoff discussed her work in finding ways to optimize therapeutic cancer cell research in developing innovative and accessible cancer treatments. Her research focuses on immunotherapy, where scientists will train a cancer patient's cells to fight back against cancer. However, the scale of implementing this type of treatment is limited, so Temenoff and her lab aim to expand the scope of research and accessibility for cell therapy.
Temenoff discussed her work to improve the manufacturing process of this research. High manufacturing costs and complex production processes have limited patient access. Through her work with CMaT, Temenoff and her collaborators are developing ways to grow larger quantities of therapeutic cells while maintaining their quality and effectiveness. A key part of this work involves creating the right environment for cells to grow, as well as developing more efficient processes.
By improving how therapeutic cells are produced, stored, and distributed, researchers hope to reduce costs and expand access to treatments. Researchers across the center are exploring applications in a variety of areas, including blood cancer, cardiovascular conditions, bone marrow-related diseases, and regenerative medicine.
Temenoff also discussed the importance of looking beyond the laboratory when considering the future of cell therapy, as collaboration across disciplines is needed for broader accessibility. From ensuring that cells maintain their quality throughout production and transportation to addressing the financial and logistical challenges of delivering treatments, these factors all play a role in bringing innovative therapies to patients.
Through this work, Temenoff and the broader CMaT research community are addressing one of the most important challenges in advanced medicine, ensuring that promising cell-based treatments can move beyond the laboratory and reach the patients who need them.
Director of Research Melissa Kemp
Melissa Kemp, professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, was recently featured on Holy Shift!, a podcast highlighting the latest biomedical research and innovations from both institutions. Kemp also serves as the Deputy Director at the Marcus Center of Excellence for Cell Biomanufacturing and Director of Research at the NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT)
In this episode, titled "Computing Cancer," Kemp discusses with host Angela Gill Nelms how computational modeling, biological data, and laboratory experiments are helping researchers better understand disease and why patients can respond differently to the same treatment. The conversation offers a look at how engineering and medicine come together to advance more personalized approaches to healthcare.
Kemp's research focuses on how metabolism and cellular signaling influence cell behavior. Her lab develops computer models that bring together information about proteins, enzymes, and other biological components to predict how cells respond to different conditions and treatments.
One exciting application for her work is cancer research. Kemp and her collaborators used existing patient data to build personalized models across several cancer types, including breast cancer, glioblastoma, and lung cancer. By looking across these models, the team identified patterns that help explain why some cancer cells are more sensitive to radiation treatment than others.
Kemp's team also conducts laboratory experiments to test its predictions and see whether the results hold up in real biological systems. This combination of modeling and experimental research could help explain why certain treatments work for some patients but not others, potentially guiding more informed treatment decisions and reducing exposure to therapies that may be less effective.
Beyond cancer, Kemp's research explores Parkinson's disease, stem cell behavior, and lung inflammation. She also discusses the broader possibilities of personalized medicine, highlighting how factors such as genetics, lifestyle, diet, and environmental exposures all contribute to human health. Her long-term goal is to develop computational tools that bring these factors together to better predict disease and identify potential treatments. Through her work, Kemp is helping researchers make sense of the complexity of biology and bringing us closer to a future where healthcare can be better tailored to each individual.
Written by DaYou Choi
Media Contact: Ashlie Bowman | Communications Manager
Parker H. Petit Institute for Bioengineering and Bioscience